Enliven Therapeutics, Inc.
ELVN
$20.63
$0.311.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 11.24% | -23.14% | -0.10% | -16.07% | 12.26% |
| Total Depreciation and Amortization | 9.46% | -7.50% | 0.00% | 2.56% | -1.27% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.28% | 6.74% | 8.69% | 54.28% | -2.85% |
| Change in Net Operating Assets | 112.54% | -389.41% | -110.22% | 213.78% | 5.42% |
| Cash from Operations | 29.30% | -40.25% | -41.09% | 40.33% | 12.53% |
| Capital Expenditure | -595.00% | -- | 100.00% | -1,000.00% | 90.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -12,777.95% | 99.04% | -95.10% | 144.11% | -88.43% |
| Cash from Investing | -12,965.38% | 96.29% | -95.10% | 144.04% | -88.23% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 93,223.93% | -99.41% | 3,478.51% | -38.15% | -98.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 93,223.93% | -99.41% | 3,478.51% | -38.15% | -98.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 178.93% | -195.62% | 526.56% | 107.17% | -206.67% |